anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a Phase I, open-label (all people know the identity of the intervention) study to investigate the single dose and steady state pharmacokinetics of telaprevir in patients with moderate hepatic impairment, and measure the relative unbound plasma concentrations of telaprevir. In addition, a small group of patients with severe hepatic impairment will be included to further characterize the pharmacokinetics of telaprevir as a function of liver disease. In this study 24 patients will be enrolled. Based upon physical examination and laboratory assessments, patients will be scored and classified into hepatic function groups on the basis of the Child-Pugh classification (Classification is based on Child-Pugh score which is used to assess prognosis of chronic hepatic disease). A Child-Pugh score of 7 to 9 is considered Child-Pugh category B (CPB) and indicative of moderate liver function impairment; a Child-Pugh score of 10 or greater is considered Child Pugh category C (CPC), indicative of severe liver impairment. Hepatic function groups will consists of Group 1: 10 patients with moderate hepatic impairment (CPB 7 to 9\]); Group 2: 10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (+5 years or -5 years) and body mass index (BMI) (+15% or -15%); Group 3: 4 patients with severe hepatic impairment (CPC \[limited to Child Pugh score 10 to 12\]). Safety and tolerability evaluations including adverse events, clinical laboratory tests, 12-lead electrocardiogram, vital signs and physical examination will be recorded throughout the study period.
OBJECTIVE: To explore the effect of enhanced recovery after surgery nursing on the recovery in patients after liver transplantation.
METHODS: This study was performed in 128 patients underwent liver transplantation in our hospital. According to the random number table, these patients were divided into the control group (n = 64) and the experimental group (n = 64). Patients in the control group received traditional nursing, while those in the experimental group received enhanced recovery after surgery nursing. Completion time of the operation, the amount of infused red blood cells during operation, intraoperative anhepatic period, intensive care unit (ICU) stay, the total length of hospitalization, the number of patients reintubated after surgery, the survival rate within 1 year after surgery, and the incidence of postoperative complications were compared between the two groups.
RESULTS: Intraoperative anhepatic period and the amount of infused red blood cells during operation in the experimental group were lower than those in the control group (both P < .05). Postoperative ICU stay, the total length of hospitalization, and the number of patients reintubated after surgery in the experimental group were decreased when compared with the control group, while postoperative ventilator weaning time was increased (all P < .05). The survival rates at 3 months, 6 months, and 1 year after surgery in the experimental group were higher than those in the control group (all P < .05). Compared with the control group, the total incidence of complications in the experimental group was reduced (P < .05).
CONCLUSION: The application of enhanced recovery after surgery nursing in liver transplantation patients contributes to the accelerated recovery of body function, shortened total length of hospitalization and ICU stay, declined complications, and increased survival rate within 1 year.
The efficacy of Fludeoxyglucose F-18 Injection in positron emission tomography cancer imaging was demonstrated in 16 independent studies. These studies prospectively evaluated the use of Fludeoxyglucose F-18 in patients with suspected or known malignancies, including non-small cell lung cancer, colo-rectal, pancreatic, breast, thyroid, melanoma, Hodgkin's and non-Hodgkin's lymphoma, and various types of metastatic cancers to lung, liver, bone, and axillary nodes. All these studies had at least 50 patients and used pathology as a standard of truth. The Fludeoxyglucose F-18 Injection doses in the studies ranged from 200 MBq to 740 MBq with a median and mean dose of 370 MBq.

In the studies, the diagnostic performance of Fludeoxyglucose F-18 Injection varied with the type of cancer, size of cancer, and other clinical conditions. False negative and false positive scans were observed. Negative Fludeoxyglucose F-18 Injection PET scans do not exclude the diagnosis of cancer. Positive Fludeoxyglucose F-18 Injection PET scans can not replace pathology to establish a diagnosis of cancer. Non-malignant conditions such as fungal infections, inflammatory processes and benign tumors have patterns of increased glucose metabolism that may give rise to false-positive scans. The efficacy of Fludeoxyglucose F-18 Injection PET imaging in cancer screening was not studied.
Tuberculous meningitis (TBM) is the most severe complication of tuberculosis (TB) and is associated with high rates of disability and mortality. Mycobacterium tuberculosis (M. tb), the infectious agent of TB, disseminates from the respiratory epithelium, breaks through the blood-brain barrier, and establishes a primary infection in the meninges. Microglia are the core of the immune network in the central nervous system (CNS) and interact with glial cells and neurons to fight against harmful pathogens and maintain homeostasis in the brain through pleiotropic functions. However, M. tb directly infects microglia and resides in them as the primary host for bacillus infections. Largely, microglial activation slows disease progression. The non-productive inflammatory response that initiates the secretion of pro-inflammatory cytokines and chemokines may be neurotoxic and aggravate tissue injuries based on damages caused by M. tb. Host-directed therapy (HDT) is an emerging strategy for modulating host immune responses against diverse diseases. Recent studies have shown that HDT can control neuroinflammation in TBM and act as an adjunct therapy to antibiotic treatment. In this review, we discuss the diverse roles of microglia in TBM and potential host-directed TB therapies that target microglia to treat TBM. We also discuss the limitations of applying each HDT and suggest a course of action for the near future.
Dosage of carbidopa may be adjusted by adding or omitting one-half or one tablet a day. Because both therapeutic and adverse responses occur more rapidly with combined therapy than when only levodopa is given, patients should be monitored closely during the dose adjustment period. Specifically, involuntary movements will occur more rapidly when carbidopa and levodopa are given concomitantly than when levodopa is given without carbidopa. The occurrence of involuntary movements may require dosage reduction. Blepharospasm may be a useful early sign of excess dosage in some patients.

  


Current evidence indicates other standard antiparkinsonian drugs may be continued while carbidopa and levodopa are being administered. However, the dosage of such other standard antiparkinsonian drugs may require adjustment.
Patients to carry out a conventional double ovarian stimulation and to receive daily injections of gonadotropins. Retrospective group (data retrieved from strictly selected treatments carried out in our institution within the 24 months prior to the inclusion of the first patient in the study group and according to the standard guideline of the clinic).
An imbalance between energy intake and energy expenditure predisposes obesity and its related metabolic diseases. Soluble dietary fiber has been shown to improve metabolic homeostasis mainly via microbiota reshaping. However, the application and metabolic effects of insoluble fiber are less understood. Herein, we employed nanotechnology to design citric acid-crosslinked carboxymethyl cellulose nanofibers (CL-CNF) with a robust capacity of expansion upon swelling. Supplementation with CL-CNF reduced food intake and delayed digestion rate in mice by occupying stomach. Besides, CL-CNF treatment mitigated diet-induced obesity and insulin resistance in mice with enhanced energy expenditure, as well as ameliorated inflammation in adipose tissue, intestine and liver and reduced hepatic steatosis, without any discernible signs of toxicity. Additionally, CL-CNF supplementation resulted in enrichment of probiotics such as Bifidobacterium and decreased in the relative abundances of deleterious microbiota expressing bile salt hydrolase, which led to increased levels of conjugated bile acids and inhibited intestinal FXR signaling to stimulate the release of GLP-1. Taken together, our findings demonstrate that CL-CNF administration protects mice from diet-induced obesity and metabolic dysfunction by reducing food intake, enhancing energy expenditure and remodeling gut microbiota, making it a potential therapeutic strategy against metabolic diseases.
PURPOSE: A food composition and a pharmaceutical composition are provided to improve an intestinal function, and to alleviating constipation by inducing intestine activation in experimental animals and indicating an excellent improvement effect on mucous secretion in the intestines. CONSTITUTION: A food composition includes a rice fermentation extract. The rice fermentation extract is manufactured from the following steps: Rice is mixed with water, soaked, and heated to be gelatinized. 0.05-10 weight% of rice wine starter is added to the gelatinized rice, and saccharified at 20-40 deg.C for 10-30 hours. The saccharified product is fermented at 15-40 deg.C for 1-10 days. The fermented product is sterilized and concentrated. The rice fermentation extract comprises 0-10 weight% of moisture, 0-3 weight% of ash, 60-95 weight% of carbohydrates, 5-30 weight% of saccharides, 0-10 weight% of crude protein, 0-0.1 weight% of crude fat, 0-0.1 weight% of saturated fat, 0-0.1 weight% of trans-fat, 0-0.1mg/100g of cholesterol, and 0-500mg/100g of sodium. The food composition additionally includes sitologically acceptable food additives.
Drug: 68Ga-AAZTA-093 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
A method for computer-assisted exercise is described. The method includes loading a definition for the exercise including an ordered list of steps. Each step includes positions, and each position is defined by constraints. For each step in the ordered list, the method loads the current step, receives an image of a patient performing the exercise; and determines a plurality of keypoints in the image. For each constraint, a determination is made as to whether the constraint is being met by the patient based, at least in part, on the relative locations of the plurality of keypoints. In response to determining a first set of constraints in the position is met by the patient, the method proceeds to a next step in the ordered list of steps. Methods for authoring the definitions for the exercises are also described.
A prospective questionnaire study will be conducted regarding the quality of life among women undergoing hormonal diagnostics due to anovulation. The study will include women aged 18-45 with ovulation disorders: PCOS (arm 1) and HPOD (arm 2). The quality of life will be assessed using the self-assessment method using the SF-36 questionnaire (Short Form Health Survey). The questionnaire is intended for a subjective assessment of health status. It consists of 11 questions containing 36 statements that allow you to determine eight quality of life indicators, i.e.: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, general health, health change.

The percentage score on a scale of 0-100% in each of the 8 life domains will be compared between both arms of the study.
Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic composition containing an algae-derived useful component and excellent in adsorptivity and its production method.  <P>SOLUTION: The cosmetic composition comprises a hydrolyzate of algae. Cyanophyta is preferable as the algae; alga of the genus Arthospira is especially preferable. The composition may contain a peptide mixture of which the hydrolyzate has an average molecular weight of 100-20,000, and the composition may be subjected to a colorant removal treatment. In the production method of the composition, algae is hydrolyzed with an acid, an alkali, or an enzyme, thus giving a cosmetic composition comprising a hydrolyzate of the algae. Before or after the hydrolysis treatment, a colorant removal step may be set.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants will receive fixed dose of 40 mg of Selinexor oral tablet on Days 1, 8, 15, and 22 of each 28-day cycle followed by Pomalidomide 4 mg PO on Days 1 through 21 of each 28-day cycle and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone dose 20 mg QW for those of \>75 years old at the Investigator's discretion, before QW dosing of Selinexor; it may be divided over 1 to 4 days at the Investigator's discretion).
A single instillation of Ruvidar® (TLD-1433) (at the therapeutic dose of 0.7 mg/cm\^2) will be infused intravesically into the bladder for approximately 60 minutes. PDT treatment is performed after Ruvidar® (TLD-1433) has been rinsed from the bladder. Two Study Treatments will be performed, a primary Study Treatment at Day 0 and a maintenance Study Treatment at Day 180.
Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
The invention provides an antioxidant peptide in perilla seeds and an application thereof. The sequence of the antioxidant peptide is Tyr-Leu(YL). In vitro experiments show that the polypeptide can effectively remove ABTS, superoxide anions and various reactive oxide species (ORAC). Meanwhile, the peptide can effectively inhibit linoleic acid and rat liver lipid peroxidation. Cell experiments prove that the peptide is safe to cells and has obvious inhibiting effects on oxidative damages of the cell HepG-2. The antioxidant peptide has the characteristics of simple structure, safety, strong antioxidation activity, and the like, can serve as an excellent substitute for existing synthetic antioxidants and has important value for development and application of novel antioxidant health care products and food additives.
Clinics will have data evaluated for up to 3 years. Wave 2 clinics will begin the iPATH practice transformation in Year 2.
An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
Participants in this study were hormone-receptor-positive HER2-negative patients with advanced breast cancer who had previously used CDK4/6 inhibitors. Hormone receptor positive HER2 negative was defined as ER positive (IHC ER positive percentage \> 10% or PR positive (IHC PR positive percentage \> 10%) and HER2 negative (IHC-/+; Or IHC++ but FISH/CISH-).

The Department of Pathology and the Key Laboratory of Breast Cancer of Fudan University Shanghai Cancer Center conducted digital pathological typing of the biopsy pathology of metastatic lesions of all participants . If the pathology of metastatic lesions could not be obtained, the digital pathological typing was performed according to the pathology of primary lesions. According to the digital pathological types of biopsy tissue and peripheral blood ctDNA, the patients were divided into four precise subtypes: SNF1, SNF2, SNF3, and SNF4. At the same time, the negative control group was randomly set by subtype stratification at 2:1. In different SNF types, patients were divided into 7 subcohorts according to the genetic PANEL results.
Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
A radioisotope elution system is provided, that has at least a component comprised in a cabinet and accessible via a door equipped with an authentication system to ensure safety. The system may also have a user interface equipped with an authentication system. It is also provided a radioisotope elution system that has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. Advantageously, the lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. In another feature, there is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.
As many patients with chronic urticaria display heightened levels of stress before and/or after the onset of the urticaria, the purpose of this study is to evaluate the effect of psychological stress intervention on chronic urticaria. Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques. Control group participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention. All participants will complete a packet of psychological and dermatological questionnaires before the first session with the psychiatry resident and one week after the final session. All participants will record daily 1) their urticaria symptoms and 2) the type and number of antihistamines taken. Blood and saliva samples will be collected before the first session and one week after completion of the final session to compare the levels of stress hormones and cytokines in order to evaluate an effect on immune dysregulation.
Upper respiratory tract infections (URI's) are a significant health burden in childhood. URI's are a major reason for visits to health care providers, and up to 35 percent of young children at any given time are taking some over-the-counter cold medication. Unfortunately, data suggest that most of these medications have limited effectiveness. Alternative medical therapies are growing in popularity; in a recent survey of parents of children being seen by pediatricians in Seattle, Washington, 24.2 percent indicated that their child had been seen by an alternative medicine health care provider, and 53.3 percent received therapies for the treatment of URI's in children. The proposed study is a randomized, double blind, placebo controlled trial of Echinacea for the treatment of URI's in children 2-11 years old. The aims of the project are: to determine if Echinacea shortens the duration and/or lessens the severity of URI's, if children receiving Echinacea for treatment of URI's have a reduced rate of secondary bacterial infections, and to determine if the use of Echinacea in patients 2-11 years old is associated with any significant side effects. A two-year study of 600 children is planned. Not only will the results of this study determine if Echinacea, the most popular medicinal herb sold in the United States, is an effective therapy for URI's in children, the study will provide a design framework for further assessment on the efficacy of other complementary and alternative medicines in children.
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
The invention provides a traditional Chinese medicine drug for treating neonatal jaundice and a preparation method thereof. The traditional Chinese medicine drug is prepared by mixing and smashing 13-18 parts by weight of bark and leaves of abelia macrotera (Graebn. et Buchw.) Rehd. and 2-3 parts by weight of herba artemisiae scopariae, extraction is conducted, and patches or injections or smearing preparations or oral preparations are obtained to treat the neonatal jaundice. The traditional Chinese medicine drug is prepared from pure natural plants, essence is taken, the drug properties are fully exerted, the curative effect is significant, and no toxic or side effect exists. The distribution of raw materials is wide, collection is convenient, the preparation method is simple, the cost is low, and the effect is significant.
One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
PURPOSE:A cosmetic having high safety, improved emulsification stability, good touch and appearance free from skin stimulation obtained by blending bentonite containing cation exchange sodium ion, water-soluble high polymer, e.g., xanthan gum, etc. oily substance, and water. CONSTITUTION:0.05-1.9wt% Bentonite containing at least 100mg equivalent/100g cation exchange sodium ion is blended with a water-soluble high polymer selected from xanthan gum, carrageenan, and hydroxypropylcellulose, oily substance, and water to give the desired skin cosmetic. The cosmetic has substantially neither stimulation to the skin nor allergy, high safety, improved emulsification stability, stability with days, good touch and appearance. A liquid oily substance, liquid paraffin, their combination with higher fatty acid monoglyceride, etc. are preferable as the oily substance. Bentonite preferably has a viscosity of 4wt% water dispersion of 150-800cp.